Back to the Top 100
PathAI logo

Rank 16AI & Clinical Intelligence

PathAI

Applies machine learning and artificial intelligence to improve pathology diagnostic accuracy and accelerate oncology drug development.

Visit website
Signal Score
91.9
Total raised
$250M
Stage
Series C
Founded
2016
Headquarters
Boston, United States
Region
North America

Their signal

By partnering with major biopharma players, PathAI transforms pathology from subjective qualitative assessment to highly reproducible, AI-quantified clinical insights.

Signal Score 91.9editorial estimate, see how it is built
Capital (25% weight)93

Total raised, quality of investors and recency of the last round.

Growth (25% weight)90

Revenue trajectory, customer count, hiring and market pull.

Clinical & regulatory (20% weight)94

Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.

Team (15% weight)93

Founder track record, clinical depth on the bench and technical leadership.

Online visibility (15% weight)89

Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.

Also in AI & Clinical Intelligence

Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.